Verastem Updates Q1 Results, Highlights Phase II/III Oncology Pipeline Progress
Verastem Therapeutics published its first-quarter earnings snapshot on May 7, outlining operating highlights and pipeline advancements without disclosing revenue or EPS figures. The update emphasized continued investment in small-molecule oncology candidates, including Phase II and III trials for defactinib and VS-6766.
1. Q1 Earnings Snapshot Released
Verastem Therapeutics released its financial update for the quarter ended March 31, focusing on operational highlights rather than detailed financial metrics. The snapshot highlighted ongoing development of key oncology assets, notably defactinib in Phase III solid tumor trials and VS-6766 in Phase II studies, underscoring the company’s commitment to its pipeline.
Related News
ENHA
Enhanced Trial Shifts to Five-Year Monitoring After 91% Athlete Testosterone Use
ENHA•
SLAB
Silicon Labs SoC Powers 500,000 Wi-SUN Module Shipment for India Grid
SLAB•
TJX
TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch
TJX•
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
VBCH
Vanguard’s BondBuilder Suite Amasses $242M in Two Months, Fuels $70B ETF Segment
VBCH•
Sources
F